November 11, 2020
Article
D. Ross Camidge, MD, PhD discusses the role of targeted therapy and how it is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer.
August 25, 2020
Video
Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.
August 18, 2020
Video
Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.
August 10, 2020
Article
Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.
May 23, 2020
Article
The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.
December 16, 2019
Article
Treatment with entrectinib led to an overall response rate of 77% and a median duration of response of 24.6 months in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated findings of a pooled analysis published in Lancet Oncology.